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We present a time-saving alternative to individual bowel loop delineation for abdomino-pelvic
Stereotactic Ablative Radiotherapy. Here, individual bowel loop contouring is only performed within a
3 cm circumferential and 2 cm superio-inferior expansion of the PTV. A bowel bag structure represents
distal bowel. No relevant doses are ‘missed’ with this time-saving strategy.
 2020 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and
Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
There is increasing interest in the use of Stereotactic Ablative
Radiotherapy (SABR) for treating nodal, bone and liver oligometas-
tases in the abdomino-pelvic region. While data demonstrates that
such an approach results in encouraging local control and suggests
potential benefits in terms of progression free survival [1,2], these
previously unirradiated or simply irradiated patients now receive
complex radiotherapy treatments, thus increasing workloads
across the radiotherapy pathway.
UK guidelines specify organ at risk (OAR) constraints for the
small bowel (a point maximum and doses to 5 cm3 and 10 cm3)
and colon (a point maximum) [3]. In many institutions, including
our own, this is applied to individual bowel loops, thus mandating
that all individual bowel loops are delineated on all planning CT
slices that contain the PTV and on all slices for approximately
2 cm above and below the PTV to allow adequate dose representa-
tion on the radiotherapy plan. Narrow slice CT scans are employed
for SABR treatments (usually 1 mm or 2 mm thickness), thus mul-
tiple slices must be delineated and interpolation tools within plan-
ning systems, designed to hasten contouring, are often imperfectfor complex structures such as the bowel. Contouring individual
bowel loops for SABR planning is therefore a time-consuming
process, often taking at least one hour based on local experience.
Intuitively the highest doses will be delivered to loops of bowel
in closest proximity to the target, calling into question the value
of the time spent delineating bowel loops across the entirety of
each CT slice.
This report aims to demonstrate the validity of contouring only
those individual bowel loops in closest proximity to the target,
while using the bowel bag to represent the dose received by those
bowel loops positioned further from the target.2. Methods
This retrospective study used datasets from 20 patients who
received SABR for oligometastatic abdomino-pelvic nodal disease
at Leeds Cancer Centre between July 2016 and October 2018. All
patients received a prescription dose of 30 Gy in 5 fractions. No
margin was added to the GTV to form the CTV (i.e. GTV = CTV)
and a 5 mm isotropic margin was added to create the PTV. Individ-
ual bowel loops (colon delineated separately from small bowel)
had been previously contoured on all slices covering the PTV and
for 2 cm above and below the PTV, as part of the normal planning
process (Fig. 1a). Small bowel constraints consisted of: maximum
dose (to 0.5 cm3; Dmax0.5cm3): 30 Gy (optimal) or 35 Gy
Fig. 1. a) Current solution (all bowel loops contoured), b) Defining proximal vs.
distal bowel loops, c) Proximal bowel loops, d) Distal bowel loops, e) Distal bowel
bag and f) Proposed contouring solution.
E. Clarke et al. / Clinical and Translational Radiation Oncology 24 (2020) 60–64 61(mandatory) in 5 fractions. In addition, the dose limit to the hottest
5 cm3 of small bowel (D5cm3) was 25 Gy in 5 fractions (optimal)
but could be relaxed such that the dose to the hottest 10 cm3 of
small bowel (D10cm3) was 25 Gy in 5 fractions (mandatory). For
the colon, Dmax0.5 cm3 was 32 Gy (optimal) and 38 Gy (manda-
tory) in 5 fractions.3. Structure segmentation
All segmentation was performed using Monaco (Version 5.1,
Elekta AB, Stockholm, Sweden). For the purposes of this project,
individual small bowel and colon loops were combined to form
an ‘All_bowel_loops’ structure. The bowel loops considered as
being in closest proximity to the target were those contained
within a 3 cm circumferential and 2 cm superio-inferior expansion
of the PTV (Fig. 1b). This margin was applied to the PTV and the
intersection of this and all bowel loops within this volume were
labelled ‘Proximal_bowel_loops’ (Fig. 1c). Bowel loops beyond
those contained within the 3/2cm PTV expansion (i.e. non-
Proximal_bowel_loops) were labelled as ‘Distal_bowel_loops’
(Fig. 1d). The bowel bag was then contoured on all slices from
2 cm above to 2 cm below the PTV, using the RTOG atlas for guid-
ance[4]. The 3/2cm expansion around the PTV was subtracted from
the bowel bag structure to create the ‘Distal_bowel_bag’ (Fig. 1e).
4. Dosimetric analysis
The maximum doses (to 0.5 cm3; Dmax0.5cm3) and doses to the
hottest 5 cm3 (D5cm3) and 10 cm3 (D10cm3) of the following struc-
tures were evaluated:
 Proximal_bowel_loops (Fig. 1c)
 Distal_bowel_loops (Fig. 1d)
 Distal_bowel_bag (Fig. 1e)
 All_bowel_loops (Fig. 1a)
4.1. Statistics
Spearman’s Rho (r) assessed potential monotonic correlations
between bowel doses to the Distal_bowel_bag and Distal_bowel_-
loops. The Wilcoxon-Signed Rank Test was used to compare
Dmax0.5 cm3, D5cm3 and D10cm3 between Proximal_bowel_loops
and Distal_bowel_loops.
5. Approvals
The project was reviewed and approved by the local Research
and Innovation Department, who considered it as a service evalu-
ation project.
6. Results
Doses to Proximal_bowel_loops were significantly higher than
doses to Distal_bowel_loops (p < 0.001 for Dmax0.5cm3, D5cm3
and D10cm3), reflecting that bowel loops closest to the target are
those that receive the highest doses and are therefore most critical
for planning based on maximum dose and ‘hot’ dose constraints,
as are commonlyused for SABR. In keepingwith this finding, the vast
majority of dose metrics were higher for Proximal_bowel_loops
than for Distal_bowel_loops. For Dmax0.5cm3, as expected, the dose
to Proximal_bowel_loops was higher in all cases (Proxi-
mal_bowel_loops minus Distal_bowel_loops median (and range):
15.4 (1.71–21.4)Gy (Fig. 2a). In one case, D10cm3 was higher (by
0.7 Gy) for the Distal_bowel_loops than for the Proxi-
mal_bowel_loops. In one other case, both the D5cm3 and D10cm3
were higher to the Distal_bowel_loops than for the Proxi-
mal_bowel_loops (by 0.1 Gy and 2.4 Gy respectively). In both these
cases, however, the absolute values were well within tolerance
levels (Proximal_bowel_loops vs. Distal_bowel_loops: Case 1:
D10cm3: 6.5 Gy vs. 7.2 Gy; Case 2: D5cm3 and D10cm3: 10.7 Gy vs.
10.8 Gy and 7.6 Gy vs. 9.9 Gy respectively) and were adequately
reflected by the dose received by the Distal_bowel_bag (see below).
Fig. 2. a) Dose differences between Proximal bowel loops and Distal bowel loops, b) Dose differences between Distal bowel bag and Distal bowel loops and, c) Dose
differences between All bowel loops and Proximal bowel loops.
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were strongly correlated (Spearman’s rho 0.84, 0.83 and 0.79 for
Dmax0.5 cm3, D5cm3 and D10cm3 respectively (p < 0.001 for all).The median difference in Dmax0.5cm3 to Distal_bowel_loops
and Distal_bowel_bag was (Distal_bowel_bag minus
Distal_bowel_loops) 0.4 Gy (range: 0.2 to +7.0), with the dose
Table 1
Dosimetric summary statistics.
Dose metric Structure Median dose (Gy) Range (Gy)
Dmax0.5cm3 Proximal bowel loops 25.5 11.7–34.0
Distal bowel loops 10.2 4.6–15.7
All bowel loops 25.5 11.7–34.0
Distal bowel bag 11.4 8.3–15.7
D5cm3 Proximal bowel loops 16.0 8.2–28.8
Distal bowel loops 8.7 3.5–14.6
All bowel loops 16.0 8.9–28.8
Distal bowel bag 10.2 7.1–14.9
D10cm3 Proximal bowel loops 12.1 6.5–24.3
Distal bowel loops 7.8 3.0–14.1
All bowel loops 12.1 7.6–24.3
Distal bowel bag 9.4 6.5–14.6
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Where the Distal_bowel_bag received a lower dose than Distal_-
bowel_loops, this was always < 0.2 Gy, likely reflecting small
(real-world) inconsistencies in contouring and small differences
in voxel assignment (inside or outside of structure edge) when cre-
ating intersecting/copied structures, which are clinically
insignificant.
Similarly, the median difference in D5cm3 to Distal_bowel_-
loops and Distal_bowel_bag was 1.0 Gy (range: +0.1 to +7.2), with
dose to the Distal_bowel_bag being higher in all patients. In addi-
tion, the median difference in D10cm3 to Distal_bowel_loops and
Distal_bowel_bag was 1.2 Gy (range: +0.3 to +7.2), with dose to
the Distal_bowel_bag being higher in all patients (Fig. 2b).
Where doses to the Distal_bowel_bag were higher than those
for Distal_bowel_loops, this represents regions of bowel bag in rel-
atively close proximity to the target, which did not contain bowel
loops at the time of CT simulation.
Minimal differences were observed between the Dmax0.5cm3,
D5cm3 and D10cm3 to Proximal_bowel_loops and All_bowel_loops
(median (and range) for All_bowel_loops minus Proxi-
mal_bowel_loops Dmax0.5cm3, D5cm3 and D10cm3 respectively:
0 (0–0 Gy), 0 (0–1.1 Gy) and 0 (0–3.2 Gy) (Fig. 2c)).
Dosimetric summary statistics are provided in Table 1.7. Discussion
This work has demonstrated that contouring individual bowel
loops in close proximity to the target provides the relevant struc-
tures to limit high dose to individual bowel loops during planning
that is based on commonly adopted SABR dose constraints (Fig. 1f
and Fig. 3). Contouring the bowel bag only beyond this region does
not result in any meaningful under-estimation of dose to bowel
loops within this region (Fig. 1f). Doses to distal_bowel_loopsFig. 3. Axial and sagittal slice showing dose distribution in relation to the PTand distal_bowel_bag displayed strong monotonic positive correla-
tions, further reassuring users of this technique that doses to the
distal_bowel_bag are reflective of those received by the dis-
tal_bowel_loops. Having applied this technique locally, small
bowel contouring times have reduced from around one hour to
no more than 15 min. This approach therefore offers substantial
time-saving implications.
The bowel bag has previously been identified as an alternative
and faster method of bowel contouring [5] and one which allows
for inter/intra-fraction changes in bowel position. The bowel bag
contains both small and large bowel. It is acknowledged that bowel
OAR constraints depend on the method used for bowel segmenta-
tion [6]. Individual bowel loop contouring has been shown to be
superior to bowel bag in terms of predicting gastrointestinal toxi-
city [7] and this approach is favoured in situations where doses to
small and large bowel are of importance [8], as is the case with
abdomino-pelvic SABR. Contouring individual bowel loops, how-
ever, is time consuming. We have provided a time saving alterna-
tive, which provides the most relevant bowel loop dosimetric
information without the need to contour all bowel across all CT
slices. A restricted bowel loop contouring approach has also been
used in the setting of online adaptive radiotherapy [9], a situation
where contouring all individual bowel loops is impractical.
For this project both large and small bowel were combined into
a single structure. The purpose of the project was to evaluate doses
to any bowel proximal and distal to the target to ensure no rele-
vant doses were being ‘missed’, rather than to analyse individual
small vs. large bowel doses. That said, this process has now been
adopted clinically, with the small and large bowel being separately
contoured within the 3/2cm expansion around the PTV. Equally,
one might opt to contour all bowel as one structure and apply
the most conservative constraint to all bowel within the 3/2cm
expansion, accepting that this may limit planning flexibility. At
present, using the technique described here in clinical practice,
the dose to the distal bowel bag is merely recorded (and ensured
to be within the same constraints as applied for the proximal
bowel loops), rather than used for optimisation. Going forward,
however, it may be possible to use this structure within the opti-
misation process, thereby further limiting low dose spread. This
would require separate evaluation.
This process can be used for abdomino-pelvic SABR using a con-
ventional linac but is also relevant for MR-linac treatments, when
rapid re-contouring for online adaptation is required [10]. The pro-
cess may also be relevant for non-SABR targets (where the target
does not include the whole pelvis) but this should be formally eval-
uated. Situations where mean bowel loop dose constraints are also
used are likely to require contouring of the entire bowel structure,
although the whole bowel bag could potentially be used as a time
saving alternative. A 3/2cm expansion was used around the PTV inV 3/2cm expansion. Dark blue colourwash represents the 10 Gy isodose.
64 E. Clarke et al. / Clinical and Translational Radiation Oncology 24 (2020) 60–64this project as visually this consistently contained all high and
intermediate dose isodose and is in keeping with the approach
for limited volume online adaptive planning [9]. For larger volume
(lower dose) Dxcm3 constraints, evaluating dose to bowel within a
3/2cm expansion alone could, in some cases, under-estimate the
dose received by all bowel loops or distal bowel loops, thus it
should be ensured that all relevant isodoses are contained within
any selected PTV expansion and that doses to the distal bowel
bag are always evaluated in conjunction with those to the proximal
bowel loops. Similarly, for higher prescription doses or constraints,
and where OAR maxima are being pushed to these limits, a larger
expansion may be required.
8. Conclusions
Contouring individual bowel loops in close proximity to an
abdomino-pelvic SABR target provides the relevant structures to
limit high dose to individual bowel loops during planning when
using commonly adopted SABR dose constraints. Contouring the
bowel bag only beyond this region does not result in any meaning-
ful under-estimation of dose to more distal bowel loops. This has
substantial time saving implications.
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